{
    "id": 10005,
    "fullName": "MCL1 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MCL1 over exp indicates an over expression of the Mcl1 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4170,
        "geneSymbol": "MCL1",
        "terms": [
            "MCL1",
            "bcl2-L-3",
            "BCL2L3",
            "EAT",
            "Mcl-1",
            "MCL1-ES",
            "mcl1/EAT",
            "MCL1L",
            "MCL1S",
            "TM"
        ]
    },
    "variant": "over exp",
    "createDate": "08/04/2015",
    "updateDate": "12/04/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9406,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sabutoclax decreased live cell number in an acute myeloid leukemia cell line expressing high levels of MCL1 in culture (PMID: 26045609).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 2577,
                "therapyName": "Sabutoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4092,
                    "pubMedId": 26045609,
                    "title": "Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26045609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9405,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, (-)BI97D6 induced apoptosis and decreased cell number in an acute myeloid leukemia cell line expressing high levels of MCL1 in culture (PMID: 26045609).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 3281,
                "therapyName": "(-)BI97D6",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4092,
                    "pubMedId": 26045609,
                    "title": "Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26045609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3376,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring stabilized Mcl1 expression in culture (PMID: 23274910).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 1077,
                "therapyName": "Vorinostat",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 570,
                    "pubMedId": 23274910,
                    "title": "Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23274910"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8233,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cell lines with elevated Mcl1 expression level demonstrated resistance to Venclexta (venetoclax) in culture (PMID: 27103402).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 1562,
                "therapyName": "Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6583,
                    "pubMedId": 27103402,
                    "title": "Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27103402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6390,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human hepatocellular carcinoma cell lines over-expressing MCL1 were resistant to 17-demethoxy-reblastatin induced apoptosis in culture (PMID: 26323360).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 4122,
                "therapyName": "17-Demethoxy-reblastatin",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5539,
                    "pubMedId": 26323360,
                    "title": "17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26323360"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3745,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MCL1 conferred resistance to ABT-737 in lymphoma cells in culture and mouse models (PMID: 17097561).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 1772,
                "therapyName": "ABT-737",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4095,
                    "pubMedId": 17097561,
                    "title": "The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17097561"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2683,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, cancer cells expressing Mcl1 were resistant to ABT-737 in culture (PMID: 22898329).",
            "molecularProfile": {
                "id": 10008,
                "profileName": "MCL1 over exp"
            },
            "therapy": {
                "id": 1772,
                "therapyName": "ABT-737",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3384,
                    "pubMedId": 22898329,
                    "title": "Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22898329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4863,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment did not inhibit proliferation of lymphoma cell lines harboring MYC amplification, PTEN deficiency, and overexpressing Mcl1 in culture (PMID: 18708578).",
            "molecularProfile": {
                "id": 19402,
                "profileName": "MCL1 over exp MYC amp PTEN dec exp"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19077,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax) and VU661013 combination therapy induced apoptosis and synergistically reduced tumor burden in a patient-derived xenograft (PDX) model of BCL2-positive and MCL1-dependent disseminated acute myeloid leukemia compared to Venclexta (venetoclax) treatment (PMID: 30185627).",
            "molecularProfile": {
                "id": 33895,
                "profileName": "BCL2 pos MCL1 over exp"
            },
            "therapy": {
                "id": 8905,
                "therapyName": "Venetoclax + VU661013",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16724,
                    "pubMedId": 30185627,
                    "title": "A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30185627"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19762,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Venclexta (venetoclax)-resistant acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) and overexpressing MCL1 demonstrated sensitivity to LAM-003 treatment in culture, and reduced tumor burden and increased survival in a cell line xenograft model (PMID: 31751472).",
            "molecularProfile": {
                "id": 34505,
                "profileName": "FLT3 exon 14 ins MCL1 over exp"
            },
            "therapy": {
                "id": 7362,
                "therapyName": "LAM-003",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17544,
                    "pubMedId": 31751472,
                    "title": "LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31751472"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19768,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LAM-003 and Venclexta (venetoclax) combination treatment synergistically reduced viability of Venclexta (venetoclax)-resistant acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) and overexpressing MCL1 in culture (PMID: 31751472).",
            "molecularProfile": {
                "id": 34505,
                "profileName": "FLT3 exon 14 ins MCL1 over exp"
            },
            "therapy": {
                "id": 9208,
                "therapyName": "LAM-003 + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17544,
                    "pubMedId": 31751472,
                    "title": "LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31751472"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10008,
            "profileName": "MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19402,
            "profileName": "MCL1 over exp MYC amp PTEN dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33895,
            "profileName": "BCL2 pos MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34505,
            "profileName": "FLT3 exon 14 ins MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34509,
            "profileName": "BCL2 pos FLT3 exon 14 ins MCL1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}